Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

Learn more about whether Alvotech or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

The determination comes after recruitment and dosing in certain trials were paused after a young patient died due to acute ...

Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...

Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Also Read: Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death Preliminary results for trontinemab from 114 participants in the 1.8 or 3.6 mg/kg suggest a rapid and ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from the ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for Duchenne muscular dystrophy. Read more here.

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...